Kidney Disease

49-64 of 145

When and how to initiate SGLT2i in CKD
When and how to initiate SGLT2i in CKD
4 things to know about CKD and SGLT2i
When and how to initiate SGLT2i in CKD
- Prof. David Wheeler, MD
What is the evidence of SGLT2i in CKD?
What is the evidence of SGLT2i in CKD?
4 things to know about CKD and SGLT2i
What is the evidence of SGLT2i in CKD?
- Prof. Hiddo L. Heerspink, PhD
Inflammation as a new target in CV risk reduction
Inflammation as a new target in CV risk reduction
Inflammation
Inflammation as a new target in CV risk reduction
- Paul Ridker, MD
Optimizing GDMT in HFrEF and management of hyperkalemia
Optimizing GDMT in HFrEF and management of hyperkalemia
Kidney Disease
Optimizing GDMT in HFrEF and management of hyperkalemia
- Prof. Mikhail Kosiborod
New perspectives in managing heart failure and hyperkalemia - The cardiorenal angle
New perspectives in managing heart failure and hyperkalemia - The cardiorenal angle
Kidney Disease
New perspectives in managing heart failure and hyperkalemia - The cardiorenal angle
- Prof. Mikhail Kosiborod
- Prof. Austin G. Stack, MD
A new option for cardiorenal protection for patients with CKD and T2DM
A new option for cardiorenal protection for patients with CKD and T2DM
Kidney Disease
A new option for cardiorenal protection for patients with CKD and T2DM
- Prof. Gerasimos S. Filippatos, MD
- Javier Morales, MD
- Angela Yee-Moon Wang, MD, PhD
Reducing morbidity and mortality in patients with CKD and T2DM
Reducing morbidity and mortality in patients with CKD and T2DM
Kidney Disease
Reducing morbidity and mortality in patients with CKD and T2DM
- Pam R. Taub, MD, FACC, FASPC
- Prof. George Bakris, MD
- Prof. Gerasimos Filippatos, MD
Composite endpoint of CV death or kidney disease worsening reduced by SGLT2i in CKD
Composite endpoint of CV death or kidney disease worsening reduced by SGLT2i in CKD
AHA 2022
Composite endpoint of CV death or kidney disease worsening reduced by SGLT2i in CKD
- David Preiss, PhD
SGLT2i in HFmrEF and HFpEF across the spectrum of glycemia
SGLT2i in HFmrEF and HFpEF across the spectrum of glycemia
Is HFpEF hiding in your practice? An expert debate on the emerging role of diabetologists
SGLT2i in HFmrEF and HFpEF across the spectrum of glycemia
- Prof. Silvio Inzucchi
The spectrum of therapeutic options: which therapies to consider?
The spectrum of therapeutic options: which therapies to consider?
The challenge of choosing in cardiovascular risk management
The spectrum of therapeutic options: which therapies to consider?
- Prof. Ulf Landmesser
SGLT2i reduces outcomes in HFmrEF and HFpEF regardless of glycemic status
SGLT2i reduces outcomes in HFmrEF and HFpEF regardless of glycemic status
EASD 2022
SGLT2i reduces outcomes in HFmrEF and HFpEF regardless of glycemic status
- Pardeep Jhund, MD, PhD
SGLT2i improves outcomes in HFpEF and HFmrEF
SGLT2i improves outcomes in HFpEF and HFmrEF
ESC 2022
SGLT2i improves outcomes in HFpEF and HFmrEF
- Scott Solomon, MD
Totality of evidence of SGLT2 inhibition in HF
Totality of evidence of SGLT2 inhibition in HF
ESC 2022
Totality of evidence of SGLT2 inhibition in HF
- Muthiah Vaduganathan, MD
All patients with HF regardless of EF benefit from SGLT2i
All patients with HF regardless of EF benefit from SGLT2i
ESC 2022
All patients with HF regardless of EF benefit from SGLT2i
- Pardeep Jhund, MD, PhD
Expanding evidence on SGLT2i: Where are we now and what can we expect?
Expanding evidence on SGLT2i: Where are we now and what can we expect?
When to start using SGLT2i in HFrEF? Initiating guideline-recommended treatment options
Expanding evidence on SGLT2i: Where are we now and what can we expect?
- Scott Solomon, MD
Discussion - When to start using SGLT2i in HFrEF? Initiating guideline-recommended treatment options
Discussion - When to start using SGLT2i in HFrEF? Initiating guideline-recommended treatment options
When to start using SGLT2i in HFrEF? Initiating guideline-recommended treatment options
Discussion - When to start using SGLT2i in HFrEF? Initiating guideline-recommended treatment options

4/9